Transperineal Intraprostatic Injection of PRX302 Under Ultrasound Guidance for Management of Prostatic Hyperplasia (TRIUMPH-1)

Sophiris Bio Corp

Status and phase

Completed

Phase 2

Conditions

Benign Prostatic Hyperplasia

Treatments

Drug: PRX302

Drug: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT00889707

PRX302-2-03

Details and patient eligibility

About

The purpose of this study is to determine whether PRX302 is safe and effective in the treatment of moderate to severe Benign Prostatic Hyperplasia (BPH).

Full description

This is a randomized, double-blinded, placebo-controlled study of transperineal intraprostatic injection of PRX302 under sonographic guidance. Subjects will be randomly assigned to the two treatment groups in a ratio of 2:1 between PRX302 and Placebo, stratified by prostate size and baseline IPSS.

Enrollment

92 patients

Sex

Male

Ages

40 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Males aged 40 to 80 years;
Lower urinary tract symptoms (LUTS), such as frequency, nocturia, urgency, weak urine stream, hesitancy, intermittency or post-void dribbling attributable to BPH for at least 6 months prior to dosing;
Untreated, intolerant or refractory to α-blockers; should not have received the medication for at least 2 weeks prior to screening and 4 weeks prior to dosing;
Subjects with PSA values 4 - 10 ng/mL should be assessed or medical records checked (e.g. biopsy report) to rule out the presence of prostate cancer;
Untreated, intolerant or intolerant to 5-α reductase inhibitors AND must be off medication for at least 6 months prior to dosing;
IPSS of 15 or higher;
Prostate volume at screening estimated at 30 to 100 mL as determined by TRUS;
Provided written Informed Consent for participation in the study.

Exclusion criteria

Maximum urine flow rate (Qmax) of greater than 12 mL/sec;
Inability to void at least 150 mL of urine;
Post voiding residual urine volume (PVR) of greater than 200 mL;
Subjects unable to stand to void;
Subjects with acute or chronic bacterial prostatitis;
Using drugs (e.g. estrogen, androgen) that can produce androgen depression or anabolic steroids;
Penile prosthesis or artificial urinary sphincter;
Presence of prostatic cyst larger than 1 cm in diameter;
Unwilling to use condoms for 3 weeks post-treatment to prevent pregnancy and to avoid semen contact with partner(s);
Urethral stricture disease;
Bladder neck abnormalities/strictures;
Significant median lobe hyperplasia that contributes to outflow obstruction;
Confirmed or suspected neurogenic bladder dysfunction;
Systemic neurological disorders that may affect voiding function;
Previous pelvic surgery, trauma or radiation;
Active genitourinary infection within 7 days before screening;
Significant renal dysfunction (as evidenced by a serum creatinine > 1.6 mg/dL on the screening laboratory evaluation);
Abnormal liver function as evidenced by any of the following abnormal laboratory values being greater than 1.5 upper limit of normal (ULN) at screening:
- alkaline phosphatase (ALP);
- total bilirubin;
- alanine transferase (ALT); and/or
- aspartate aminotransferase (AST);
Abnormal Prothrombin Time (PT > 13 sec) / International Normalized Ratio (INR > 1.2);
Severe cardiovascular or hepatic disease (American Society of Anesthesiologists [ASA] > 3); Presence of suspected or confirmed malignancy other than non-melanomatous, cutaneous malignancies which have undergone curative interventions;
Receiving anticoagulants (Subjects receiving anticoagulants may be enrolled after discontinuation of anticoagulant therapy and return of INR level to within normal limits (INR < 1.2) before dosing day. Subjects receiving platelet inhibitors (including garlic) must be off the inhibitors for at least 6 days or more. Subjects unable to discontinue anticoagulant therapy may not be enrolled in this study);
Subjects who have received any treatment for BPH other than α-blockers, 5-α reductase inhibitors or phytotherapy;
Subjects taking α-blockers and phytotherapy within 2 weeks of screening and 4 weeks of dosing;
Subjects receiving 5-α reductase inhibitors within 6 months of dosing;
Subjects taking part in other experimental programs prior to the start of the study or during the study period;
Any medical, psychological or other condition or medical history of the subject that, in the opinion of the Investigator or the Sponsor's Medical Monitor, unduly increases the risk of subject's participation or that would unnecessarily confound the data to be collected in this study;
Unable or unwilling to comply with the requirements of the protocol.